Omniose (formerly VaxNewMo) is developing next generation conjugate vaccines against bacterial diseases using its patented conjugating enzyme technology. Their conjugating enzyme technology is faster, more natural, and more reliable than methods used by pharmaceutical companies.

The Omniose bioconjugate vaccine platform enables the precise enzymatic attachment of virtually any bacterial polysaccharide antigen to engineered carrier proteins within a single E. coli cell. Bioconjugation is a much simpler process than conventional chemical conjugation methods and has the potential to produce higher quality vaccines as it retains the natural polysaccharide structure elaborated by a bacterial pathogen.

Previous enzymes used for bioconjugation thus far could only address a limited range of bacterial targets. Omniose is breaking through this barrier by expanding the scope of bacterial vaccines that can be developed, while leveraging the already established benefits of bioconjugation.

For more information, visit Omniose or follow their updates on:



  • $3m

Omniose Articles

Big Pharma Teams Up with St. Louis Vaccine Startup & Why it Matters

In 2019, BioGenerator Invested $3.2 Million in 16 Bioscience Companies in St. Louis

VaxNewMo’s Vaccine Breakthrough Published in Nature

A “No” from Arch Grants Isn’t a “No” to Your Business

Bioscience Startup Founders: Expect Bumps in the Road From Academic to Entrepreneur

Meet the Next Generation of Job Creators Winning in St. Louis

18 Startups Win $50,000 Each To Locate Their Business In St Louis